Amaad Rana, MD
Rheumatology · New Haven, CTNPI 1366962417
Payments from drug & device makers
What this record shows
This record is dominated by grants: $40,000 of the $40,588 with a category attached, or 98.6%. Pfizer accounts for 98.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $40,364 and has fallen 100.0% since, to $19 in 2025.
Across 37 payments — averaging $1096.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$40K
- AbbVie$355
- Johnson & Johnson$94
- Insulet Corporation$31
- UCB, Inc.$20
- Amgen$19
- plus $30 from 2 others
What the payments were for
- Grants$40,00099%
- Food & beverage$5351%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $40,040 |
| AbbVie | 24 | $355 |
| Johnson & Johnson | 3 | $94 |
| Insulet Corporation | 1 | $31 |
| UCB, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Novartis | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$40,588 in reported general payments places this provider in the 85th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 14 | $86,128 |
| Azathioprine | 13 | $3,455 |
| Hydroxychloroquine Sulfate | 63 | $1,935 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $1,095 |
| Leflunomide | 19 | $994 |
| MethotrexateMethotrexate Sodium | 46 | $459 |
| Prednisone | 82 | $344 |
| Duloxetine Hcl | 16 | $217 |
| Folic Acid | 12 | $70 |
| Meloxicam | 24 | $48 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New Haven
- Joseph CraftNew Haven$3K
- Richard BucalaNew Haven$2K
- Charles DisabatinoNew Haven$2K
- Victor MartinNew Haven$2K
- Marissa SansoneNew Haven$1K
- Insoo KangNew Haven$1K
- Kenneth MillerDanbury$873K
- Robert SchoenGuilford$638K
- Bret SohnStamford$447K
- Fotios KoumpourasNorth Haven$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.